Patients were randomized to inhalation of tobramycin ( 80 mg/2 mL ) or placebo ( 2 mL isotonic saline ) once daily ( 4 minutes/nostril ) with the PARI Sinus nebulizer over 28 days , with all patients eligible for a subsequent course of open-label inhalation of tobramycin for 28 days .